Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1994 Oct 1;180(4):1243–1250. doi: 10.1084/jem.180.4.1243

Defective inflammatory response in interleukin 6-deficient mice

PMCID: PMC2191674  PMID: 7931061

Abstract

Systemic and localized inflammation elicit a number of host responses which include fever, cachexia, hypoglycemia, and major changes in the concentration of liver plasma proteins. Interleukin 6 (IL-6) is considered an important mediator of the inflammatory response, together with IL-1 and tumor necrosis factor alpha (TNF-alpha). The purpose of this study was to unequivocally determine the role of IL-6 in these phenomena making use of IL-6-deficient mice that we have recently generated by gene targeting. We report here that in the absence of IL- 6, mice are unable to mount a normal inflammatory response to localized tissue damage generated by turpentine injection. The induction of acute phase proteins is dramatically reduced, mice do not lose body weight and only suffer from mild anorexia and hypoglycemia. In contrast, when systemic inflammation is elicited through the injection of bacterial lipopolysaccharide (LPS), these parameters are altered to the same extent both in wild-type and IL-6-deficient mice, demonstrating that under these conditions IL-6 function is dispensable. Moreover, we show that LPS-treated IL-6-deficient mice produce three times more TNF-alpha than wild-type controls, suggesting that increased TNF-alpha production might be one of the compensatory mechanisms through which a normal response to LPS is achieved in the absence of IL-6. We also show that corticosterone is normally induced in IL-6-deficient mice, demonstrating that IL-6 is not required for the activation of the hypothalamic-pituitary-adrenal axis. Our results reinforce the idea that different patterns of cytokines are involved in systemic and localized tissue damage, and identify IL-6 as an essential mediator of the inflammatory response to localized inflammation.

Full Text

The Full Text of this article is available as a PDF (1.0 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aderka D., Le J. M., Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol. 1989 Dec 1;143(11):3517–3523. [PubMed] [Google Scholar]
  2. Aggarwal B. B., Kohr W. J., Hass P. E., Moffat B., Spencer S. A., Henzel W. J., Bringman T. S., Nedwin G. E., Goeddel D. V., Harkins R. N. Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem. 1985 Feb 25;260(4):2345–2354. [PubMed] [Google Scholar]
  3. Baumann H., Gauldie J. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol Biol Med. 1990 Apr;7(2):147–159. [PubMed] [Google Scholar]
  4. Baumann H., Hill R. E., Sauder D. N., Jahreis G. P. Regulation of major acute-phase plasma proteins by hepatocyte-stimulating factors of human squamous carcinoma cells. J Cell Biol. 1986 Feb;102(2):370–383. doi: 10.1083/jcb.102.2.370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Baumann H., Richards C., Gauldie J. Interaction among hepatocyte-stimulating factors, interleukin 1, and glucocorticoids for regulation of acute phase plasma proteins in human hepatoma (HepG2) cells. J Immunol. 1987 Dec 15;139(12):4122–4128. [PubMed] [Google Scholar]
  6. Baumann H., Ziegler S. F., Mosley B., Morella K. K., Pajovic S., Gearing D. P. Reconstitution of the response to leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in hepatoma cells. J Biol Chem. 1993 Apr 25;268(12):8414–8417. [PubMed] [Google Scholar]
  7. Besedovsky H., del Rey A., Sorkin E., Dinarello C. A. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science. 1986 Aug 8;233(4764):652–654. doi: 10.1126/science.3014662. [DOI] [PubMed] [Google Scholar]
  8. Beutler B., Milsark I. W., Cerami A. C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985 Aug 30;229(4716):869–871. doi: 10.1126/science.3895437. [DOI] [PubMed] [Google Scholar]
  9. Billiar T. R., Curran R. D., Williams D. L., Kispert P. H. Liver nonparenchymal cells are stimulated to provide interleukin 6 for induction of the hepatic acute-phase response in endotoxemia but not in remote localized inflammation. Arch Surg. 1992 Jan;127(1):31–37. doi: 10.1001/archsurg.1992.01420010037006. [DOI] [PubMed] [Google Scholar]
  10. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  11. Dinarello C. A. Interleukin-1 and the pathogenesis of the acute-phase response. N Engl J Med. 1984 Nov 29;311(22):1413–1418. doi: 10.1056/NEJM198411293112205. [DOI] [PubMed] [Google Scholar]
  12. Dittrich F., Thoenen H., Sendtner M. Ciliary neurotrophic factor: pharmacokinetics and acute-phase response in rat. Ann Neurol. 1994 Feb;35(2):151–163. doi: 10.1002/ana.410350206. [DOI] [PubMed] [Google Scholar]
  13. Fey G. H., Hattori M., Northemann W., Abraham L. J., Baumann M., Braciak T. A., Fletcher R. G., Gauldie J., Lee F., Reymond M. F. Regulation of rat liver acute phase genes by interleukin-6 and production of hepatocyte stimulating factors by rat hepatoma cells. Ann N Y Acad Sci. 1989;557:317–331. doi: 10.1111/j.1749-6632.1989.tb24024.x. [DOI] [PubMed] [Google Scholar]
  14. Gershenwald J. E., Fong Y. M., Fahey T. J., 3rd, Calvano S. E., Chizzonite R., Kilian P. L., Lowry S. F., Moldawer L. L. Interleukin 1 receptor blockade attenuates the host inflammatory response. Proc Natl Acad Sci U S A. 1990 Jul;87(13):4966–4970. doi: 10.1073/pnas.87.13.4966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hirano T., Akira S., Taga T., Kishimoto T. Biological and clinical aspects of interleukin 6. Immunol Today. 1990 Dec;11(12):443–449. doi: 10.1016/0167-5699(90)90173-7. [DOI] [PubMed] [Google Scholar]
  16. Kioussis D., Hamilton R., Hanson R. W., Tilghman S. M., Taylor J. M. Construction and cloning of rat albumin structural gene sequences. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4370–4374. doi: 10.1073/pnas.76.9.4370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kopf M., Baumann H., Freer G., Freudenberg M., Lamers M., Kishimoto T., Zinkernagel R., Bluethmann H., Köhler G. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 1994 Mar 24;368(6469):339–342. doi: 10.1038/368339a0. [DOI] [PubMed] [Google Scholar]
  18. Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci. 1982;389:39–48. doi: 10.1111/j.1749-6632.1982.tb22124.x. [DOI] [PubMed] [Google Scholar]
  19. Metcalf D., Nicola N. A., Gearing D. P. Effects of injected leukemia inhibitory factor on hematopoietic and other tissues in mice. Blood. 1990 Jul 1;76(1):50–56. [PubMed] [Google Scholar]
  20. Morrone G., Ciliberto G., Oliviero S., Arcone R., Dente L., Content J., Cortese R. Recombinant interleukin 6 regulates the transcriptional activation of a set of human acute phase genes. J Biol Chem. 1988 Sep 5;263(25):12554–12558. [PubMed] [Google Scholar]
  21. Murakami T., Ohnishi S., Nishiguchi S., Maeda S., Araki S., Shimada K. Acute-phase response of mRNAs for serum amyloid P component, C-reactive protein and prealbumin (transthyretin) in mouse liver. Biochem Biophys Res Commun. 1988 Sep 15;155(2):554–560. doi: 10.1016/s0006-291x(88)80530-8. [DOI] [PubMed] [Google Scholar]
  22. Nikkilä H., Gitlin J. D., Muller-Eberhard U. Rat hemopexin. Molecular cloning, primary structural characterization, and analysis of gene expression. Biochemistry. 1991 Jan 22;30(3):823–829. doi: 10.1021/bi00217a036. [DOI] [PubMed] [Google Scholar]
  23. Northemann W., Andus T., Gross V., Nagashima M., Schreiber G., Heinrich P. C. Messenger RNA activities of four acute phase proteins during inflammation. FEBS Lett. 1983 Sep 19;161(2):319–322. doi: 10.1016/0014-5793(83)81033-3. [DOI] [PubMed] [Google Scholar]
  24. Oldenburg H. S., Rogy M. A., Lazarus D. D., Van Zee K. J., Keeler B. P., Chizzonite R. A., Lowry S. F., Moldawer L. L. Cachexia and the acute-phase protein response in inflammation are regulated by interleukin-6. Eur J Immunol. 1993 Aug;23(8):1889–1894. doi: 10.1002/eji.1830230824. [DOI] [PubMed] [Google Scholar]
  25. Parant M., Le Contel C., Parant F., Chedid L. Influence of endogenous glucocorticoid on endotoxin-induced production of circulating TNF-alpha. Lymphokine Cytokine Res. 1991 Aug;10(4):265–271. [PubMed] [Google Scholar]
  26. Perlstein R. S., Mougey E. H., Jackson W. E., Neta R. Interleukin-1 and interleukin-6 act synergistically to stimulate the release of adrenocorticotropic hormone in vivo. Lymphokine Cytokine Res. 1991 Apr;10(1-2):141–146. [PubMed] [Google Scholar]
  27. Perlstein R. S., Whitnall M. H., Abrams J. S., Mougey E. H., Neta R. Synergistic roles of interleukin-6, interleukin-1, and tumor necrosis factor in the adrenocorticotropin response to bacterial lipopolysaccharide in vivo. Endocrinology. 1993 Mar;132(3):946–952. doi: 10.1210/endo.132.3.8382602. [DOI] [PubMed] [Google Scholar]
  28. Pfeffer K., Matsuyama T., Kündig T. M., Wakeham A., Kishihara K., Shahinian A., Wiegmann K., Ohashi P. S., Krönke M., Mak T. W. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell. 1993 May 7;73(3):457–467. doi: 10.1016/0092-8674(93)90134-c. [DOI] [PubMed] [Google Scholar]
  29. Piechaczyk M., Blanchard J. M., Marty L., Dani C., Panabieres F., El Sabouty S., Fort P., Jeanteur P. Post-transcriptional regulation of glyceraldehyde-3-phosphate-dehydrogenase gene expression in rat tissues. Nucleic Acids Res. 1984 Sep 25;12(18):6951–6963. doi: 10.1093/nar/12.18.6951. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Poli V., Balena R., Fattori E., Markatos A., Yamamoto M., Tanaka H., Ciliberto G., Rodan G. A., Costantini F. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 1994 Mar 1;13(5):1189–1196. doi: 10.1002/j.1460-2075.1994.tb06368.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Ray A., LaForge K. S., Sehgal P. B. On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion. Mol Cell Biol. 1990 Nov;10(11):5736–5746. doi: 10.1128/mcb.10.11.5736. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Rothe J., Lesslauer W., Lötscher H., Lang Y., Koebel P., Köntgen F., Althage A., Zinkernagel R., Steinmetz M., Bluethmann H. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature. 1993 Aug 26;364(6440):798–802. doi: 10.1038/364798a0. [DOI] [PubMed] [Google Scholar]
  33. Schotanus K., Tilders F. J., Berkenbosch F. Human recombinant interleukin-1 receptor antagonist prevents adrenocorticotropin, but not interleukin-6 responses to bacterial endotoxin in rats. Endocrinology. 1993 Dec;133(6):2461–2468. doi: 10.1210/endo.133.6.8243265. [DOI] [PubMed] [Google Scholar]
  34. Schreiber G., Howlett G., Nagashima M., Millership A., Martin H., Urban J., Kotler L. The acute phase response of plasma protein synthesis during experimental inflammation. J Biol Chem. 1982 Sep 10;257(17):10271–10277. [PubMed] [Google Scholar]
  35. Shiels B. R., Northemann W., Gehring M. R., Fey G. H. Modified nuclear processing of alpha 1-acid glycoprotein RNA during inflammation. J Biol Chem. 1987 Sep 15;262(26):12826–12831. [PubMed] [Google Scholar]
  36. Sibbald W. J., Short A., Cohen M. P., Wilson R. F. Variations in adrenocortical responsiveness during severe bacterial infections. Unrecognized adrenocortical insufficiency in severe bacterial infections. Ann Surg. 1977 Jul;186(1):29–33. doi: 10.1097/00000658-197707000-00005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Sipe J. D., Gonnerman W. A., Loose L. D., Knapschaefer G., Xie W. J., Franzblau C. Direct binding enzyme-linked immunosorbent assay (ELISA) for serum amyloid A (SAA). J Immunol Methods. 1989 Dec 20;125(1-2):125–135. doi: 10.1016/0022-1759(89)90085-9. [DOI] [PubMed] [Google Scholar]
  38. Steel D. M., Rogers J. T., DeBeer M. C., DeBeer F. C., Whitehead A. S. Biosynthesis of human acute-phase serum amyloid A protein (A-SAA) in vitro: the roles of mRNA accumulation, poly(A) tail shortening and translational efficiency. Biochem J. 1993 May 1;291(Pt 3):701–707. doi: 10.1042/bj2910701. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Strassmann G., Fong M., Windsor S., Neta R. The role of interleukin-6 in lipopolysaccharide-induced weight loss, hypoglycemia and fibrinogen production, in vivo. Cytokine. 1993 Jul;5(4):285–290. doi: 10.1016/1043-4666(93)90058-d. [DOI] [PubMed] [Google Scholar]
  40. Taga T., Kishimoto T. Cytokine receptors and signal transduction. FASEB J. 1992 Dec;6(15):3387–3396. doi: 10.1096/fasebj.6.15.1334470. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES